Rafael Amado Sells 9,910 Shares of Zai Lab (NASDAQ:ZLAB) Stock

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) insider Rafael Amado sold 9,910 shares of the company’s stock in a transaction that occurred on Thursday, April 2nd. The shares were sold at an average price of $20.39, for a total value of $202,064.90. Following the completion of the transaction, the insider owned 59,761 shares in the company, valued at approximately $1,218,526.79. The trade was a 14.22% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Rafael Amado also recently made the following trade(s):

• On Friday, March 13th, Rafael Amado sold 2,957 shares of Zai Lab stock. The shares were sold at an average price of $18.63, for a total value of $55,088.91.

Zai Lab Stock Performance

NASDAQ:ZLAB remained flat at $20.41 during trading hours on Friday. The company’s stock had a trading volume of 707,427 shares, compared to its average volume of 746,471. The firm has a market capitalization of $2.30 billion, a PE ratio of -12.68 and a beta of 0.86. The stock has a 50-day moving average of $18.63 and a 200 day moving average of $21.91. Zai Lab Limited Unsponsored ADR has a twelve month low of $15.96 and a twelve month high of $44.34.

Zai Lab (NASDAQ:ZLAB) last posted its quarterly earnings results on Saturday, February 14th. The company reported ($0.50) earnings per share for the quarter. Zai Lab had a negative return on equity of 22.81% and a negative net margin of 38.15%.The firm had revenue of $127.60 million for the quarter. As a group, equities research analysts expect that Zai Lab Limited Unsponsored ADR will post -2.58 earnings per share for the current year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Zai Lab stock. Royal Bank of Canada lifted its position in Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) by 214.3% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 13,771 shares of the company’s stock after purchasing an additional 9,390 shares during the quarter. Royal Bank of Canada’s holdings in Zai Lab were worth $498,000 at the end of the most recent quarter. 41.65% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts have weighed in on ZLAB shares. UBS Group started coverage on shares of Zai Lab in a research report on Wednesday, January 7th. They set a “buy” rating and a $35.00 target price for the company. Cantor Fitzgerald dropped their price target on shares of Zai Lab from $55.00 to $37.00 and set an “overweight” rating on the stock in a research note on Friday, February 27th. JPMorgan Chase & Co. cut their price objective on shares of Zai Lab from $39.00 to $32.00 and set an “overweight” rating for the company in a report on Wednesday, March 18th. Jefferies Financial Group upgraded shares of Zai Lab to a “strong-buy” rating in a research note on Monday, January 19th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Zai Lab in a report on Wednesday, January 21st. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $50.00.

About Zai Lab

Zai Lab Ltd (NASDAQ: ZLAB) is a biopharmaceutical company focused on the research, development, manufacturing and commercialization of innovative therapies. Headquartered in Shanghai, China, Zai Lab operates R&D centers in Asia and the United States and maintains commercial offices across Greater China, North America, Europe and Australia. The company’s end-to-end platform encompasses discovery biology, translational development, clinical research and global supply chain management.

The company’s marketed portfolio is anchored by Brukinsa (zanubrutinib), a next-generation Bruton’s tyrosine kinase inhibitor approved for several B-cell malignancies.